Aventis Pharma is shopping for an agency to handle its Nasacort nasal spray for allergies, the company confirmed.
A representative for the Bridgewater, N.J., pharmaceuticals marketer, while confirming that the firm is looking for an agency for Nasacort, declined to give details on the review or say who has handled the brand so far.
Sources said the competition could be close to completion.
Aventis spent $8 million on Nasacort from March, when the first spending was recorded, through May, according to CMR, projecting to an estimated $30 million annual outlay.
The company's other major allergy medication, Allegra, is now handled by McCann-Erickson in New York. The $50 million brand was moved to McCann from Leo Burnett in March following a review that also involved Ogilvy & Mather in New York and other undisclosed agencies. Burnett did not participate in that review.
According to material from the company, Nasacort's point of difference is that it becomes thicker when it hits its target in the nasal area, minimizing "troublesome run-off."